Predictive value of basal follicle-stimulating hormone concentrations in a general subfertility population Joris M van Montfrans, M.D., Annemieke Hoek,

Slides:

Advertisements

Similar presentations

Pregnancy rates after embryo transfer depend on the provider at embryo transfer22 Rhonda M Hearns-Stokes, M.D., Bradley T Miller, M.D., Lynette Scott,

Advertisements

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Miscarriage risk for IVF pregnancies in poor responders to ovarian hyperstimulation Maaike L Haadsma, Henk Groen, Thea M Mooij, Curt W Burger, Frank JM.

Time to pregnancy after a previous miscarriage in subfertile couples

Impact of chemotherapeutics and advanced testicular cancer or Hodgkin lymphoma on sperm deoxyribonucleic acid integrity Cristian O'Flaherty, Ph.D., Barbara.

Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.

Diminished ovarian reserve as measured by means of baseline follicle-stimulating hormone and antral follicle count is not associated with pregnancy loss.

Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M

Miscarriage risk for IVF pregnancies in poor responders to ovarian hyperstimulation Maaike L Haadsma, Henk Groen, Thea M Mooij, Curt W Burger, Frank JM.

Evaluation of basal estradiol levels in assisted reproductive technology cycles2 John L Frattarelli, M.D., Paul A Bergh, M.D., Michael R Drews, M.D.,

Michele A. Hanson, M.D., Daniel A. Dumesic, M.D.

Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.

The predictive value for in vitro fertility delivery rates is greatly impacted by the method used to select the threshold between normal and elevated.

Mike Ripley, M. D. , F. R. C. S. C. , Andrea Lanes, M. Sc

Janet Kwee, M. D. , Roel Schats, M. D. , Ph. D. , Joseph McDonnell, M

James P Toner, M.D., Ph.D. Fertility and Sterility

The value of Chlamydia trachomatis–specific IgG antibody testing and hysterosalpingography for predicting tubal pathology and occurrence of pregnancy

Hongxia Li, M. D. , Jiangang Chen, M. D. , James W Overstreet, M. D

Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization.

Hakan Cakmak, M. D. , Audra Katz, R. N. , Marcelle I. Cedars, M. D

Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D.

Zeev Shoham, M.D. Fertility and Sterility

Diminished ovarian reserve as measured by means of baseline follicle-stimulating hormone and antral follicle count is not associated with pregnancy loss.

High serum luteinizing hormone and testosterone concentrations do not predict pregnancy outcome in women with recurrent miscarriage Luciano G Nardo,

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

Elevated follicle-stimulating hormone levels and the chances for azoospermic men to become fathers after retrieval of elongated spermatids from cryopreserved.

Evaluating the performance of serum antimullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine.

Chao-Chin Hsu, M. D. , Ph. D. , Hsin-Chih Kuo, Ph. D

When do involuntarily infertile couples choose to seek medical help?

A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin.

David E. Reichman, M.D., Dan Goldschlag, M.D., Zev Rosenwaks, M.D.

Mohamed A.M Hassan, M.Sc., Stephen R Killick, M.D.

Tomer Singer, M. D. , David H. Barad, M. D. , M. S

Paolo Vercellini, M. D. , Silvia Maddalena, M. D. , Olga De Giorgi, M

Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis Rina Agrawal,

Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study Carlo.

Concentrations of inhibins and activin in women undergoing stimulation with recombinant follicle-stimulating hormone for in vitro fertilization treatment

Luteal estradiol administration strengthens the relationship between day 3 follicle- stimulating hormone and inhibin B levels and ovarian follicular status

A. Criniti, G. Chow, A. Khabani, L. Scott, N.A. Klein

Abnormal endometrial development occurs during the luteal phase of nonsupplemented donor cycles treated with recombinant follicle-stimulating hormone.

Predictive usefulness of cycle day 10 follicle-stimulating hormone level in a clomiphene citrate challenge test for in vitro fertilization outcome in.

Comparison of basal follicle-stimulating hormone versus the clomiphene citrate challenge test for ovarian reserve screening Tarun Jain, M.D., Michael.

Atsushi Yanaihara, M. D. , Ph. D. , Takeshi Yorimitsu, M. D

A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro.

Regulation of assisted reproductive technologies in the United States

Cost-effectiveness of hysterosalpingography, laparoscopy, and Chlamydia antibody testing in subfertile couples Ben W.J Mol, M.D., Ph.D., John A Collins,

Matthew S. Christman, M. D. , Suzanne R. Gudeman, M. D. , Justin J

Apichart Chittacharoen, M.D., Yongyoth Herabutya, F.R.C.O.G.

Moderately elevated levels of basal follicle-stimulating hormone in young patients predict low ovarian response, but should not be used to disqualify.

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Fertility and Sterility

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization Efstratios M Kolibianakis, M.D., Kostas.

Geoffrey M.H. Waites, Sc.D. Fertility and Sterility

Fertility and Sterility

Peter F Donderwinkel, M. D

First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for.

Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function David H. Barad, M.D., M.S., Andrea Weghofer,

Egg production predicts a doubling of in vitro fertilization pregnancy rates even within defined age and ovarian reserve categories Melissa C. Yih, M.D.,

Effectiveness of human menopausal gonadotropin versus recombinant follicle- stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive.

Performance of basal follicle-stimulating hormone and patient's age in the prediction of poor ovarian response and IVF outcome of women who developed.

Early menopause in mothers of children with Down syndrome?

Early pregnancy loss in in vitro fertilization (IVF) is a positive predictor of subsequent IVF success G.Wright Bates, M.D., Elizabeth S Ginsburg, M.D.

Intrafollicular antimüllerian hormone levels predict follicle responsiveness to follicle- stimulating hormone (FSH) in normoandrogenic ovulatory women.

Platelet-activating factor significantly enhances intrauterine insemination pregnancy rates in non-male factor infertility William E Roudebush, Ph.D.,

Basal antral follicle number and mean ovarian diameter predict cycle cancellation and ovarian responsiveness in assisted reproductive technology cycles2

Effect of obesity on recombinant follicle-stimulating hormone absorption: subcutaneous versus intramuscular administration Michael P Steinkampf, M.D.,

Is chromosome testing of the second miscarriage cost saving

Low-dose human chorionic gonadotropin therapy can improve sensitivity to exogenous follicle-stimulating hormone in patients with secondary amenorrhea

Ernesto Bosch, M. D. , Elena Labarta, M. D

Presentation transcript:

Predictive value of basal follicle-stimulating hormone concentrations in a general subfertility population Joris M van Montfrans, M.D., Annemieke Hoek, M.D., Marcel H.A van Hooff, M.D., Corry H de Koning, M.D., Nino Tonch, M.D., Cornelis B Lambalk, M.D. Fertility and Sterility Volume 74, Issue 1, Pages 97-103 (July 2000) DOI: 10.1016/S0015-0282(00)00560-4

FIGURE 1 Cumulative PRs in patients with elevated basal FSH concentrations (n = 50) and in controls (n = 50). Time to pregnancy is defined as the period between the moment the couple started to attempt pregnancy and the date of the last menstruation followed by a pregnancy. Log-rank test for time to pregnancy, P=.27. van Montfrans. Predictive value of basal FSH. Fertil Steril 2000. Fertility and Sterility 2000 74, 97-103DOI: (10.1016/S0015-0282(00)00560-4)

FIGURE 2 Relation between cumulative PR and basal FSH category in 50 subfertile patients with basal FSH concentrations >10 IU/L. χ2 analysis, P=.59. van Montfrans. Predictive value of basal FSH. Fertil Steril 2000. Fertility and Sterility 2000 74, 97-103DOI: (10.1016/S0015-0282(00)00560-4)